Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy

Calgary, Alberta (ots/PRNewswire) -

The presentations at the ESC Congress symposium highlighted
apabetalone and the opportunity and need for a novel approach to the
treatment of high risk cardiovascular disease and diabetes.

Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today
announced that on Sunday, August 28, 2016, at the European Society of
Cardiology (ESC) Congress in Rome, Italy, the Company hosted a
symposium entitled "A novel approach for high CV risk patients with
diabetes: The potential of epigenetics."

The speakers and agenda were as follows:

Introduction

Stefano Del Prato, MD - Università di Pisa, Pisa, Italy

The High Risk Diabetes patient with cardiovascular disease:
What else
can we target to reduce cardiovascular risk?
Kausik Ray, MD -
Imperial College London, United Kingdom

Understanding BET inhibition as a novel pathway for cardiovascular
risk modulation

Jorge Plutzky, MD - Brigham and Women's Hospital, Harvard Medical
School, Boston, USA

BET inhibition in cardiovascular disease: A new dawn?

John Kastelein, MD - Academic Medical Centre, Amsterdam, The
Netherlands

Discussion & summary
Stefano Del Prato, MD - Kausik Ray, MD

Presentations will be made available at: http://www.pace-cme.org.

Donald J. McCaffery, President and CEO commented, "The
presentations at the ESC Congress symposium highlighted apabetalone
and the opportunity and need for a novel approach to the treatment of
high risk cardiovascular disease and diabetes. Moreover, data
presented demonstrated the important role for epigenetics in the
underlying pathology of these diseases". McCaffrey added that "based
on its mechanism, we believe that apabetalone has the potential to
address the significant unmet medical need in this patient
population. Importantly, we remain encouraged by the recent data
safety monitoring board review and recommendation to proceed with the
BETonMACE phase 3 trial, as planned. The trial has already attained
one quarter enrollment of the planned 2,400 patients and remains on
track with internal projections."

Resverlogix also presented a poster at the congress entitled:
"Modulation of the complement cascade in cardiovascular disease
patients by a bromodomain and extraterminal (BET) protein inhibitor".
The poster will be made available on the Resverlogix website at:http:
//www.resverlogix.com/media/presentations-publications.html#.V8Lq-pgr
Khc.

The poster contained data demonstrating that apabetalone treatment
reduced basal and cytokine-induced expression of complement factors
in hepatocytes. Furthermore, in samples from CVD patients, the
complement pathway was identified to be the top most downregulated by
apabetalone treatment. This was supported by an observed reduction in
the levels of complement proteins, which have been linked to
cardiovascular disease and major adverse cardiac events (MACE). A
reduction in the overall function of the complement cascade in plasma
from cardiovascular disease patients treated with apabetalone was
also presented.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class,
small molecule that is a selective BET (bromodomain and
extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set of
biological effects with potentially important benefits for patients
with diseases such as high-risk cardiovascular disease (CVD),
diabetes mellitus (DM), chronic kidney disease, Alzheimer's disease,
Orphan diseases, and peripheral artery disease, while maintaining a
well described safety profile. Apabetalone is the only selective BET
bromodomain inhibitor in human clinical trials, currently in a Phase
3 trial BETonMACE in high-risk CVD patients with type 2 DM and low
high-density lipoprotein (HDL).

Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).

This news release may contain certain forward-looking information
as defined under applicable Canadian securities legislation, that are
not based on historical fact, including without limitation statements
containing the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "continue", "estimate", "forecasts" and
other similar expressions. In particular, this news release includes
forward looking information relating to the Company's Phase 3
clinical trial and the potential role of apabetalone in the treatment
of CVD, DM, chronic kidney disease, Alzheimer's disease, Orphan
diseases, and peripheral artery disease. Our actual results, events
or developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no assurance
that any of the events or expectations will occur or be realized. By
their nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our Annual
Information Form and most recent MD&A which are incorporated herein
by reference and are available through SEDAR at http://www.sedar.com.
The forward-looking statements contained in this news release are
expressly qualified by this cautionary statement and are made as of
the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

For further information please visit http://www.resverlogix.com.

Follow us on Twitter: @Resverlogix_RVX
(https://twitter.com/resverlogix_rvx)
(https://twitter.com/resverlogix_rvx), or on our blog at
http://www.resverlogix.com/blog

ots Originaltext: Resverlogix Corp.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: +1-403-254-9252

Original Content von: Resverlogix Corp., übermittelt durch news aktuell